Literature DB >> 19128820

Effect of freezing method and storage at -20 degrees C and -70 degrees C on prothrombin time, aPTT and plasma fibrinogen levels.

Sonja Alesci1, Martin Borggrefe, Carl-Erik Dempfle.   

Abstract

Clinical and epidemiological trials often involve central laboratory analyses of coagulation tests, including fibrinogen, which requires freezing of the plasma samples. Although rapid freezing by immersion of sample tubes in liquid nitrogen and storage at -70 degrees C is recommended, plasma samples are often transferred directly to the storage compartments, and stored at -20 degrees C. Prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen using a kinetic fibrinogen assay, PT-derived fibrinogen, and an immunoassay were measured in fresh plasma samples from 16 healthy blood donors. In addition, four sets of aliquots were prepared. Set A was transferred directly to a -20 degrees C storage compartment, set B was first snap-frozen in liquid nitrogen and then transferred to the -20 degrees C compartment. Set C was transferred directly to a -70 degrees C freezer, set D was first snap-frozen in liquid nitrogen and then stored at -70 degrees C. Aliquots were thawed after one, two, three and four months storage and laboratory assays repeated. PT and aPTT were strongly influenced by freezing and storage. In contrast, freezing had little effect on fibrinogen levels. Differences were below three percent for all variants. Changes were smaller for samples stored at -70 degrees C compared to -20 degrees C, and for snap-frozen compared to not snap-frozen samples. Frozen and thawed samples generated slightly higher fibrinogen levels compared to fresh samples. Prothrombin time and aPTT should be measured in fresh samples, since freezing has an inconstant and unpredictable effect on the results. In contrast, freezing and storage has little effect on results of fibrinogen assays. A limitation of the study is that only samples from healthy blood donors were used. Plasma samples with abnormal fibrinogen concentration, or with abnormal concentrations of coagulation factors might behave differently.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19128820     DOI: 10.1016/j.thromres.2008.11.010

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  10 in total

1.  Amidolytic, procoagulant, and activation-suppressing proteins produced by contact activation of blood factor XII in buffer solution.

Authors:  Avantika Golas; Chyi-Huey Joshua Yeh; Christopher A Siedlecki; Erwin A Vogler
Journal:  Biomaterials       Date:  2011-09-28       Impact factor: 12.479

2.  Robust Label-free, Quantitative Profiling of Circulating Plasma Microparticle (MP) Associated Proteins.

Authors:  Sophie Braga-Lagache; Natasha Buchs; Mircea-Ioan Iacovache; Benoît Zuber; Christopher Benjamin Jackson; Manfred Heller
Journal:  Mol Cell Proteomics       Date:  2016-10-12       Impact factor: 5.911

3.  Contact activation of blood plasma and factor XII by ion-exchange resins.

Authors:  Chyi-Huey Josh Yeh; Ziad O Dimachkie; Avantika Golas; Alice Cheng; Purnendu Parhi; Erwin A Vogler
Journal:  Biomaterials       Date:  2011-10-06       Impact factor: 12.479

4.  Effect of storage conditions on prothrombin time, activated partial thromboplastin time and fibrinogen concentration on canine plasma samples.

Authors:  Giuseppe Piccione; Stefania Casella; Claudia Giannetto; Elisabetta Giudice
Journal:  J Vet Sci       Date:  2010-06       Impact factor: 1.672

5.  A comparison of blood factor XII autoactivation in buffer, protein cocktail, serum, and plasma solutions.

Authors:  Avantika Golas; Chyi-Huey Josh Yeh; Harit Pitakjakpipop; Christopher A Siedlecki; Erwin A Vogler
Journal:  Biomaterials       Date:  2012-10-30       Impact factor: 12.479

6.  Prognostic utility of biochemical markers of cardiovascular risk: impact of biological variability.

Authors:  Kristine S Alexander; Steven C Kazmierczak; Caryn K Snyder; Jon A Oberdorf; David H Farrell
Journal:  Clin Chem Lab Med       Date:  2013-09       Impact factor: 3.694

7.  Seventeen year risk of all-cause and cause-specific mortality associated with C-reactive protein, fibrinogen and leukocyte count in men and women: the EPIC-Norfolk study.

Authors:  Sara Ahmadi-Abhari; Robert N Luben; Nicholas J Wareham; Kay-Tee Khaw
Journal:  Eur J Epidemiol       Date:  2013-07-03       Impact factor: 8.082

8.  Effects of a 12-Month Pedometer-Based Walking Intervention in Women of Low Socioeconomic Status.

Authors:  Lyndsey M Hornbuckle; J Derek Kingsley; Michael R Kushnick; Robert J Moffatt; Emily M Haymes; Rebecca Miles; Tonya Toole; Lynn B Panton
Journal:  Clin Med Insights Womens Health       Date:  2016-10-06

Review 9.  Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratories.

Authors:  A Magnette; M Chatelain; B Chatelain; H Ten Cate; F Mullier
Journal:  Thromb J       Date:  2016-12-12

10.  Effects of preanalytical frozen storage time and temperature on screening coagulation tests and factors VIII and IX activity.

Authors:  Ying Zhao; Guofang Feng; Jie Zhang; Renjie Gong; Changming Cai; Limin Feng
Journal:  Sci Rep       Date:  2017-09-22       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.